NIPH Clinical Trials Search

UMIN ID: C000000020

Registered date:05/07/2005

Study of fluorouracil, epirubicin and cyclophosphamide followed by docetaxel as preoperative chemotherapy in primary breast cancer (JBCRG-02)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedPrimary breast cancer
Date of first enrollment2004/08/01
Target sample size30
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2, q3w x 4 cycles, followed by Docetaxel 100 mg/m2, q3w x 4 cycles as Primary systemic Chemotherapy


Primary OutcomeSafety, clinical and histologic effect
Secondary OutcomeBreast-conserving rate, disease-free survival

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum60years-old
Include criteria
Exclude criteriaHypersensitivity for drug Serious coexisting illness Active double cancer Bilateral breast cancer Male breast cancer Pregnant or postpartum women

Related Information


public contact
Name Katsumasa Kuroi
Address 9-4-3F, Nihonbashikoamicho, Chuo-ku, Tokyo 103-0016, Japan Japan 103-0016
Telephone 03-6264-8873
Affiliation JBCRG Head Office
scientific contact
Name Seigo Nakamura
Address 9-1 Akashi, Chuo-ku, Tokyo Japan
Telephone 03-3534-5151
Affiliation St Luke's International Hospital Breast Center